Bortezomib Induced Tumor Lysis Syndrome in Multiple Myeloma
| Autor: | Jong-Ho Won, Nam-Su Lee, Se-Hyoung Kim, Sung Kyu Park, Shinae Yu, Sung Woo Ryu, Kyoungha Kim |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty High risk patients Response to therapy business.industry Bortezomib Tumor burden medicine.disease Tumor lysis syndrome Mild symptoms immune system diseases hemic and lymphatic diseases Internal medicine Immunology medicine business Early phase Multiple myeloma medicine.drug |
| Zdroj: | Soonchunhyang Medical Science. 19:31-33 |
| ISSN: | 2233-4297 2233-4289 |
| DOI: | 10.15746/sms.13.008 |
| Popis: | The tumor lysis syndrome (TLS) commonly occurs in the lymphoproliferative disorder, either spontaneously or in response to therapy. TLS is uncommon in multiple myeloma. However, with the use of bortezomib in the treatment of multiple myeloma, cases of TLS have been reported. We report here threepatients who presented with TLS after the administration of bortezomib. Two of them presented mild symptoms and recovered with hydration only. However, death of the other patient was associated with TLS. We should monitor patients who had high tumor burden, especially in early phase of bortezomib therapy and appropriate prophylaxis for high risk patient is also needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|